Tissue plasminogen activator.

TISSUE plasminogen activator (t-PA) is a naturally occurring protein that catalyzes the conversion of the inactive proenzyme plasminogen into the active serine protease plasmin. It is one of two ma...

[1]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[2]  P. Thompson.  CORONARY THROMBOLYSIS AND MYOCARDIAL SALVAGE BY TISSUE PLASMINOGEN ACTIVATOR , 1988, The Lancet.

[3]  M. O'Rourke,et al.  Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. , 1988, Circulation.

[4]  M. Verstraete.  THROMBOLYSIS AFTER MYOCARDIAL INFARCTION , 1988, The Lancet.

[5]  H. Gold,et al.  Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. , 1988, Circulation.

[6]  P. Mombaerts,et al.  Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. , 1988, Circulation.

[7]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[8]  G. FitzGerald,et al.  Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. , 1988, Circulation.

[9]  E. Topol,et al.  A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. , 1987, The New England journal of medicine.

[10]  E. Topol,et al.  Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. , 1987, Journal of the American College of Cardiology.

[11]  H. White,et al.  Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. , 1987, The New England journal of medicine.

[12]  E. Braunwald,et al.  Update from the Thrombolysis in Myocardial Infarction Trial. , 1987, Journal of the American College of Cardiology.

[13]  S. Forman,et al.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.

[14]  R. Bolli,et al.  Activation of the complement system by recombinant tissue plasminogen activator. , 1987, Journal of the American College of Cardiology.

[15]  S. Sherry,et al.  Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction. , 1987, The American journal of medicine.

[16]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[17]  E. Topol,et al.  A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. , 1987, Journal of the American College of Cardiology.

[18]  B. Bennett,et al.  Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. , 1987, Blood.

[19]  J. Loscalzo,et al.  Tissue plasminogen activator promotes platelet disaggregation in plasma. , 1987, The Journal of clinical investigation.

[20]  H. Gold,et al.  A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris. , 1987, Circulation.

[21]  E. Ohlstein,et al.  Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit. , 1987, Thrombosis research.

[22]  L. Gold,et al.  Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Kooistra,et al.  Effect of Thrombin on the Production of Plasminogen Activators and PA Inhibitor-1 by Human Foreskin Microvascular Endothelial Cells , 1987, Thrombosis and Haemostasis.

[24]  H. Gold,et al.  Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. , 1987, Journal of the American College of Cardiology.

[25]  P. Ludbrook,et al.  Sustained Fibrinolysis After Administration of t-PA Despite Its Short Half-Life in the Circulation , 1987, Thrombosis and Haemostasis.

[26]  D. Belin,et al.  Plasminogen activator-specific inhibitors produced by human monocytes/macrophages , 1987, The Journal of experimental medicine.

[27]  Deborah L. Higgins,et al.  Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. , 1987, Biochemistry.

[28]  I. Jang,et al.  Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months. , 1986, Journal of the American College of Cardiology.

[29]  A. V. van Zonneveld,et al.  On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. , 1986, The Journal of biological chemistry.

[30]  E. Braunwald,et al.  ACUTE PULMONARY EMBOLISM TREATED WITH TISSUE PLASMINOGEN ACTIVATOR , 1986, The Lancet.

[31]  L Morgenstern,et al.  Coronary angioscopy in patients with unstable angina pectoris. , 1986, The New England journal of medicine.

[32]  E. Jaffe,et al.  Binding of plasminogen to cultured human endothelial cells. , 1986, The Journal of biological chemistry.

[33]  A. M. Lefer,et al.  Beneficial effects of tissue-type plasminogen activator in acute myocardial ischemia in cats. , 1986, Journal of the American College of Cardiology.

[34]  P. Johnson,et al.  Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. , 1986, The Journal of clinical investigation.

[35]  K. Fujikawa,et al.  Localization of the binding site of tissue-type plasminogen activator to fibrin. , 1986, The Journal of clinical investigation.

[36]  D. Rijken,et al.  Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator. , 1986, The Journal of biological chemistry.

[37]  I. Palacios,et al.  Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.

[38]  D. Collen,et al.  Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits. , 1986, Blood.

[39]  T. Gelehrter,et al.  Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. , 1986, The Journal of clinical investigation.

[40]  R. Eddy,et al.  Chromosomal locations of human tissue plasminogen activator and urokinase genes. , 1985, Science.

[41]  R. W. Brower,et al.  DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTION , 1985, The Lancet.

[42]  P. Brewster,et al.  Relation of effectiveness of intracoronary thrombolysis in acute myocardial infarction to systemic thrombolytic state. , 1985, The American journal of cardiology.

[43]  J. Vermylen,et al.  Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism. , 1985, Annals of internal medicine.

[44]  E. Plow,et al.  Binding and activation of plasminogen on the platelet surface. , 1985, The Journal of biological chemistry.

[45]  F. Sheehan,et al.  Intravenous urokinase in acute myocardial infarction. , 1985, The American journal of cardiology.

[46]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[47]  M. Aldrich,et al.  Cerebrovascular complications of streptokinase infusion. , 1985, JAMA.

[48]  A. Schafer,et al.  Plasmin inhibition of platelet function and of arachidonic acid metabolism. , 1985, The Journal of clinical investigation.

[49]  B E Sobel,et al.  Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. , 1984, Circulation.

[50]  J. Verheijen,et al.  Masking of Fibrinolytic Response to Stimulation by an Inhibitor of Tissue-Type Plasminogen Activator in Plasma , 1984, Thrombosis and Haemostasis.

[51]  K. Fujikawa,et al.  Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes , 1984, FEBS letters.

[52]  D. Loskutoff,et al.  Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. , 1984, The Journal of clinical investigation.

[53]  D. Pennica,et al.  Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. , 1984, The Journal of pharmacology and experimental therapeutics.

[54]  E. Kruithof,et al.  Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. , 1984, Blood.

[55]  L. Patthy,et al.  Importance of intramolecular interactions in the control of the fibrin affinity and activation of human plasminogen. , 1984, The Journal of biological chemistry.

[56]  F. Van de Werf,et al.  Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. , 1984, The New England journal of medicine.

[57]  E. Levin.  Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[58]  P. Wallén,et al.  An Enzyme Linked Immunosorbent Assay for Determination of Tissue Plasminogen Activator Applied to Patients with Thromboembolic Disease , 1983, Thrombosis and Haemostasis.

[59]  D. Lawrence,et al.  Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Collen,et al.  Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay. , 1983, The Journal of laboratory and clinical medicine.

[61]  P. Seeburg,et al.  Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli , 1983, Nature.

[62]  M. Rånby,et al.  Studies on the kinetics of plasminogen activation by tissue plasminogen activator. , 1982, Biochimica et biophysica acta.

[63]  M. Hoylaerts,et al.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. , 1982, The Journal of biological chemistry.

[64]  M. Hoylaerts,et al.  Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. , 1982, The Journal of biological chemistry.

[65]  C. Korninger,et al.  Neutralization of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Plasma: No Evidence for a Specific Inhibitor , 1981, Thrombosis and Haemostasis.

[66]  D. Collen,et al.  Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. , 1981, The Journal of biological chemistry.

[67]  E. Hoal,et al.  Molecular species of plasminogen activators secreted by normal and neoplastic human cells. , 1980, Cancer research.

[68]  P. Thompson,et al.  Stroke after acute myocardial infarction: relation to infarct size. , 1978, British medical journal.

[69]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[70]  S. Niewiarowski,et al.  Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis. , 1973, The Journal of clinical investigation.

[71]  J. van der Westhuyzen.  Letter: Plasma-T3 assay in kwashiorkor. , 1973, Lancet.

[72]  T. Kawano,et al.  Urokinase Inhibitor in Human Placenta , 1968, Nature.

[73]  Barr Jb,et al.  HOME OR AWAY , 1964 .

[74]  A. Todd.  The histological localisation of fibrinolysin activator. , 1959, The Journal of pathology and bacteriology.

[75]  D. D. Munro.  Eczema herpeticum (Kaposi's varicelliform eruption) in an adult. , 1959, Lancet.

[76]  T. Astrup,et al.  Fibrinolysis in the Animal Organism , 1947, Nature.